Last edition
News about " non-cystic fibrosis bronchiectasis "
Phase 2a study findings show RESP-X demonstrated safety, favourable dosing potential and encouraging efficacy signals, supporting further clinical development for respiratory patients colonised with Pseudomonas aeruginosa.
Non-Cystic Fibrosis Bronchiectasis | 25/05/2026 | By News Bureau
MHRA Approves Brensocatib as First Targeted Treatment for Non-Cystic Fibrosis Bronchiectasis in UK
UK regulator grants marketing authorisation to brensocatib (Brinsupri) for patients aged 12 and above with recurrent non-cystic fibrosis bronchiectasis flare-ups.
Non-Cystic Fibrosis Bronchiectasis | 24/02/2026 | By News Bureau | 370
Merck Completes Acquisition of Verona Pharma
The acquisition of Verona Pharma strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade.
Non-cystic Fibrosis Bronchiectasis | 08/10/2025 | By Dineshwori | 158
Fosun Pharma Industrial has signed a global License Agreement with Expedition Therapeutics Inc., granting the US-based biotechnology company the rights to develop, manufacture, and commercialise its investigational respiratory drug XH-S004 in all regions worldwide, excluding the Chinese Mainland, Hong Kong SAR, and Macau SAR.
Non-cystic Fibrosis Bronchiectasis | 13/08/2025 | By Dineshwori | 293
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy